Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

November 10, 2017: By Jon Swedien

EYLEARegeneron reported Nov. 8 that net sales of Eylea (aflibercept) in the US totaled $953 million in Q3-2017, a 12 percent increase over Q3-2016 revenues of $854 million.

Bayer commercializes Eylea outside the US. In Q3-2017, net sales of Eylea outside of the US were $564 million, compared with $471 million in the third quarter of 2016, a 20 percent increase, Regeneron said. In Q3-2017, Regeneron recognized $205 million from its share of net profit from Eylea sales outside the US, compared with $171 million in Q3-2016.

About 70 percent of Eylea sold in the US goes to treat wet age-related macular degeneration and about 25 percent goes to treat diabetic macular edema (DME), said Manisha Narasimhan, PhD, Regeneron’s head of investor relations. Narasimhan said DME represents a significant growth opportunity for Eylea because a large majority of patients are not currently using an anti-VEGF treatment.

Regeneron, based in Tarrytown, New York, posted $1.5 billion in revenues in Q3-2017, compared with $1.2 billion in Q3-2016, a 23 percent increase.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023